Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (41-50 of 175) with videos related to

Pageof 18
Sort By:
Journal of Gastroenterology and Hepatology|March 3, 2006
Hyperglycemia and biliary tract adenocarcinomaDaniel B Costa, Keith E Stuart, Silvio E Inzucchi
Clinical Lung Cancer|July 28, 2009
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathwayKim-Son H Nguyen, Susumu Kobayashi, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Serum concentrations of Erlotinib at a dose of 25 mg dailyDaniel B Costa, Susumu Kobayashi, Wee-Lee Yeo, et al.
Translational Lung Cancer Research|November 19, 2019
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?Andrew J Piper, Kartik Sehgal, Daniel B Costa, et al.
Targeted Oncology|October 27, 2023
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancerAllison Ackerman, Michael A Goldstein, Susumu Kobayashi, et al.
Targeted Oncology|October 4, 2023
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Targeted Oncology|December 9, 2023
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Translational Lung Cancer Research|September 18, 2015
Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysisErik Folch, Daniel B Costa, Jeffrey Wright, et al.
Journal of the National Cancer Institute|December 10, 2013
Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking historyGeoffrey R Oxnard, Kim-Son H Nguyen, Daniel B Costa
Pageof 18

Showing results (41-50 of 175) with videos related to

Sort By:
Pageof 18
Journal of Gastroenterology and Hepatology|March 3, 2006
Hyperglycemia and biliary tract adenocarcinomaDaniel B Costa, Keith E Stuart, Silvio E Inzucchi
Clinical Lung Cancer|July 28, 2009
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathwayKim-Son H Nguyen, Susumu Kobayashi, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Serum concentrations of Erlotinib at a dose of 25 mg dailyDaniel B Costa, Susumu Kobayashi, Wee-Lee Yeo, et al.
Translational Lung Cancer Research|November 19, 2019
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?Andrew J Piper, Kartik Sehgal, Daniel B Costa, et al.
Targeted Oncology|October 27, 2023
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancerAllison Ackerman, Michael A Goldstein, Susumu Kobayashi, et al.
Targeted Oncology|October 4, 2023
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Targeted Oncology|December 9, 2023
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A PodcastXiuning Le, Eric Nadler, Daniel B Costa, et al.
Translational Lung Cancer Research|September 18, 2015
Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysisErik Folch, Daniel B Costa, Jeffrey Wright, et al.
Journal of the National Cancer Institute|December 10, 2013
Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking historyGeoffrey R Oxnard, Kim-Son H Nguyen, Daniel B Costa
Pageof 18